Matinas Biopharma Holdings Inc. (MTNB) Financial Statements (2024 and earlier)

Company Profile

Business Address 1545 ROUTE 206 SOUTH
BEDMINSTER, NJ 07921
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments13,75628,76349,62258,67927,77512,447
Cash and cash equivalents4,7876,83021,03012,43222,17012,447
Short-term investments8,96921,93328,59246,2475,605 
Restricted cash and investments5025050136250100
Prepaid expense      539
Other undisclosed current assets1,7375,5191,3212,7401,898 
Total current assets:15,54334,53250,99361,55529,92313,085
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization21302258117
Operating lease, right-of-use asset3,0643,6134,2193,2773,761
Property, plant and equipment1,9232,0911,5381,5241,7492,043
Intangible assets, net (including goodwill)4,3534,3534,3544,3544,3544,354
Goodwill1,3361,3361,3361,3361,3361,336
Intangible assets, net (excluding goodwill)3,0173,0173,0173,0173,0173,017
Restricted cash and investments200200200200336461
Total noncurrent assets:9,56110,28710,3339,41210,3176,858
TOTAL ASSETS:25,10444,81961,32670,96740,24019,943
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1,9613,7173,7893,1452,6192,557
Interest and dividends payable   1,174
Accounts payable514618938350679296
Accrued liabilities1,4473,0992,8512,7951,9401,087
Debt572131478283
Other undisclosed current liabilities656562539391  
Total current liabilities:2,6224,2864,3493,5683,0972,840
Noncurrent Liabilities
Long-term debt and lease obligation18224,1433,3283,750108
Capital lease obligations108
Finance lease, liability182232455
Liabilities, other than long-term debt3,2183,874341341341854
Deferred rent credit      513
Deferred tax liabilities, net341
Deferred income tax liabilities341341341341341
Operating lease, liability2,8773,5334,1403,3043,696
Total noncurrent liabilities:3,2363,8964,4843,6694,091962
Total liabilities:5,8588,1828,8337,2377,1893,802
Equity
Equity, attributable to parent, including:19,24636,63752,49363,73133,05216,142
Preferred stock    3,798  
Common stock222222201611
Additional paid in capital195,018190,070184,251167,192113,42872,295
Accumulated other comprehensive income (loss)(221)(824)(145)228(1) 
Accumulated deficit(175,573)(152,631)(131,634)(107,507)(84,378)(65,945)
Other undisclosed equity, attributable to parent     3,9869,780
Total equity:19,24636,63752,49363,73133,05216,142
TOTAL LIABILITIES AND EQUITY:25,10444,81961,32670,96740,24019,943

Income Statement (P&L) ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues 1,0963,1883315890120
Gross profit: 1,0963,1883315890120
Operating expenses(24,862)(27,778)(24,768)(24,365)(19,011)(14,766)
Operating loss:(23,766)(24,590)(24,735)(24,207)(18,921)(14,647)
Nonoperating income8243,5931,4511,76054157
Investment income, nonoperating 4843,4911,3281,0731,007 
Other nonoperating income340102123686  
Interest and debt expense(3)(1)(3)(7)(12)(13)
Loss from continuing operations before income taxes:(22,945)(20,998)(23,286)(22,454)(18,392)(14,603)
Income tax benefit      507
Loss from continuing operations:(22,945)(20,998)(23,286)(22,454)(18,392)(14,096)
Loss before gain (loss) on sale of properties:(23,286)(22,454)(18,392)(14,096)
Other undisclosed net income   46,586   
Net income (loss):(22,945)(20,998)23,300(22,454)(18,392)(14,096)
Other undisclosed net income (loss) attributable to parent31(46,583)71,01913
Net loss attributable to parent:(22,942)(20,997)(23,283)(22,447)(17,373)(14,083)
Preferred stock dividends and other adjustments   (396) (339)(905)
Other undisclosed net loss available to common stockholders, basic    (793)(586) 
Net loss available to common stockholders, diluted:(22,942)(20,997)(23,679)(23,240)(18,297)(14,988)

Comprehensive Income ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net income (loss):(22,945)(20,998)23,300(22,454)(18,392)(14,096)
Other comprehensive income (loss)603(679)(374)229(1) 
Comprehensive income (loss):(22,342)(21,677)22,926(22,224)(18,393)(14,096)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent31(46,583)71,019 
Comprehensive loss, net of tax, attributable to parent:(22,339)(21,676)(23,657)(22,218)(17,374)(14,096)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: